Open Access

Pulmonary cryptococcosis coexisting with lung adenocarcinoma: A case report and review of the literature

  • Authors:
    • Hansheng Wang
    • Xiao Chen
    • Yunyun Wang
    • Dan Yu
    • Yanhui Zhou
    • Yan Liu
    • Yijun Tang
    • Meifang Wang
  • View Affiliations

  • Published online on: December 7, 2023     https://doi.org/10.3892/ol.2023.14179
  • Article Number: 47
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pulmonary cryptococcosis (PC) is an invasive pulmonary fungal disease caused by Cryptococcus neoformans or Cryptococcus gattii. It often presents as a single nodule or mass on radiology, which is easily misdiagnosed as lung cancer or metastases. However, cases of PC coexisting with lung cancer are rare and when this scenario is encountered in clinical practice, it is easy to be misdiagnosed as metastatic lung cancer. The present study reported the case of a 65‑year‑old immunocompetent patient with PC coexisting with lung adenocarcinoma. Percutaneous lung biopsy was performed on the nodule in the anterior segment of the left upper lobe and the nodule in the posterior basal segment of the left lower lobe, which were diagnosed as primary adenocarcinoma and cryptococcus, respectively. Lung cancer was treated by surgery and PC was treated successfully by antifungal treatment. During the 5‑year follow‑up, contrast‑enhanced CT showed no recurrence of either disease. This case reminds us of the possibility of dualism in the diagnosis of multiple pulmonary nodules based on CT examination, such as the coexistence of lung carcinoma and PC. In addition, early diagnosis and treatment contribute to good prognosis.

Introduction

Pulmonary cryptococcosis (PC) is a common opportunistic fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii (1), which mainly invades the respiratory system, followed by the central nervous system (CNS) (2). It usually occurs in immunocompromised patients, such as patients with human immunodeficiency virus (HIV) infection, solid organ transplantation or autoimmune diseases, as well as patients who use corticosteroids and other immunosuppressants (3,4). However, the incidence of PC has recently increased rapidly in hosts with normal immune function (5,6). Different immune statuses may affect the pulmonary CT manifestations of cryptococcosis (7,8). The diagnosis of PC is challenging due to its diverse and nonspecific CT findings, which may mimic those of lung cancer, bacterial pneumonia or tuberculosis (5). Previous studies have indicated that advanced cancer may lead to immunodeficiency and cause cryptococcosis (9,10). Previous studies have reported on PC coexisting with lung carcinoma (9,1117). Most of the reported cases presented with respiratory symptoms and a small number of them were asymptomatic. Certain cases are accompanied with other underlying diseases, such as diabetes, tumor history or systemic lupus erythematosus (11,12,14,17). In general, this coexistence relationship may be broadly divided into two types; one is that cryptococcal infection occurs in lung cancer nodules or masses (9,18); the other is that cryptococcal infection and lung cancer nodules/masses belong to two different lesions (15). It is radiologically nonspecific and is usually found by surgical excision or percutaneous lung biopsy. As with other early lung cancer, the treatment for lung cancer nodules or masses is aggressive surgical resection, while PC usually requires postoperative antifungal therapy. The prognosis of lung cancer is related to the pathological and clinical stage of lung cancer, and cryptococcal infection usually has a better prognosis. The present study reported the case of a 65-year-old patient with pulmonary adenocarcinoma complicated with PC infection.

Case presentation

A 65-year-old Han Chinese woman who worked as a crop farmer presented to Taihe Hospital (Shiyan, China) for a routine physical examination in August 2018. The patient had no respiratory symptoms and denied any other discomfort. Chest CT showed a 2.4×2.0-cm nodule in the anterior segment of the left superior lobe (Fig. 1A), which was highly suspected to be peripheral lung cancer. A 1.3×0.9-cm nodule was detected in the posterior basal segment of the left lower lobe (Fig. 1), which was suspected to be intrapulmonary metastasis. Hospitalization was recommended for further examination and treatment.

The patient denied any respiratory symptoms, such as cough, sputum, fever, chest pain, wheezing or weight loss. Immune function was normal, the patient had no history of travel or exposure to pigeon feces or soil, no history of smoking or alcohol consumption within the last month, and had not been extensively treated with hormones and/or antibiotics before coming to the hospital. The patient's medical history included surgery for varicose veins in the left lower extremity 30 years earlier, cataract surgery of the left eye 10 years ago and hemorrhoid surgery 2 years previously. On admission, the vital signs etc. were normal On physical examination, there were no skin lesions, lymphadenopathy or splenomegaly.

Laboratory examination indicated the following: Whole blood leukocytes, 4.82×109/l [neutrophils, 68.8% (normal range, 50–70%); lymphocytes, 24.3% (normal range, 20–50%); monocytes, 5.6% (normal range, 3–10%); eosinophils, 1.5% (normal range, 0.4–8%); basophils, 0% (normal range, 0–1%)]; red blood cells, 4.37×1012/l (normal range, 4.3 to 5.8×1012/l); hemoglobin, 127 g/l (normal range, 130–175 g/l); platelets, 175×109/l (normal range, 125 to 350×109/l); blood glucose, 4.45 mmol/l (normal range, 3.9–6.1 mmol/l); total bilirubin, 9.8 µmol/l (normal range, 3.42–20.5 µmol/l); aspartate aminotransferase, 17 U/l (normal range, 0–40 U/l); alanine aminotransferase, 12 U/l (normal range, 0–50 U/l); lactate dehydrogenase, 99 IU/l (normal range, 100–240 IU/l); and highly sensitive C-reactive protein, 0.15 mg/l (normal range, 0–5 mg/l). A urinalysis and microscopic examination were normal. Tumor markers were as follows: Neuron-specific enolase, 10.1 ng/ml (normal range, 0–16.3 ng/ml); carcinoembryonic antigen, 1.77 µg/l (normal range, 0–5 µg/l); and ferritin, 357 ng/ml (normal range, 30–400 ng/ml), all of which were at normal levels; however, Cyfra21-1 was 3.75 µg/l higher than the upper limit of the normal level (normal range, 0–3.3 µg/l). Sputum Gram staining (19) and bacterial culture showed no microorganisms. Acid-fast staining (20) and sputum culture showed no acid-fast bacteria. Bronchofiberscopy showed no lesions in the trachea and bronchus, and bacterial, cytological and pathological examinations from the bronchoscope provided negative results.

To obtain a definitive diagnosis, a CT-guided percutaneous lung biopsy was performed on a nodule of radiologically high suspicion of lung cancer in the anterior segment of the left upper lobe, which was pathologically confirmed to be adenocarcinoma. To evaluate the stage of lung cancer and select appropriate treatment, a CT-guided percutaneous lung biopsy was performed on the nodule in the posterior basal segment of the left inferior lobe 1 week later, which was confirmed by histopathology as PC infection. Histologically, hematoxylin & eosin staining (21) revealed granulomatous inflammation and yeast-form fungi in multinucleated cells, and cryptococcus was identified by periodic acid Schiff (PAS), Gomori methenamine silver (GMS) and mucicarmine (MC) staining (Fig. 2A-D, respectively). The above staining procedures were performed according to standard protocols. Two weeks later, the patient underwent thoracoscopic resection of the left lung cancer. Macroscopic examination revealed that the excised 14×9.5×3.5-cm upper left lobe included a 3.1×2.5×2-cm mass with gray and grayish black sections, solid, medium in texture, and indistinct from the surrounding boundary (Fig. 3). The mass was adjacent to the pleura and did not involve the bronchus. Histologically, the tumor cells were moderately to poorly differentiated adenocarcinoma of the acinar and micropapillary type (Fig. 4A-D), and no cryptococcal infection was observed. No metastatic cancer was found in the lymph nodes (0/11), the bronchial incisive margin was negative and the pathological TNM stage was T2aN0Mx. In addition, the patient received fluconazole (Pfizer Inc.) 200 mg/day antifungal therapy for 6 months. Within five years after the resection, the patient was admitted to the respiratory department of our hospital regularly for further follow-up (every 6 months for the first 2 years and once a year for the last 3 years), and the latest follow-up was in August 2023. The patient was in good condition and contrast-enhanced CT showed no recurrence of either disease (Fig. 1B, C, E and F).

Discussion

Cryptococcosis is a fatal fungal infection mainly caused by Cryptococcus neoformans or Cryptococcus gattii (1). Cryptococcosis caused by Cryptococcus neoformans is common in China (22). At present, PC is the third most common pulmonary fungal infection in China and previous studies have shown that the majority of cryptococcosis cases in China were reported in HIV-uninfected patients (particularly immunocompetent hosts) (22,23). The case of the present study was a patient with normal immune function, without any history of illness of the immune system, underlying diseases such as diabetes or use of immunosuppressants or glucocorticoids. PC can be confirmed by histopathology or tissue culture (24). In the present case, the histopathologic diagnosis of PC was obtained through biopsy, surgery and special staining, such as PAS, GMS and MC. Of course, in addition to invasive diagnostic methods, there are noninvasive methods for PC, such as blood culture and Cryptococcus antigen (CrAg) (25). However, culture often yields negative results in immunocompetent hosts (26); occasionally, histopathologically confirmed cases are culture-negative (27). The CrAg test is a sensitive and specific test for the diagnosis of cryptococcosis in immunocompromised patients (28). However, the sensitivity is lower in patients with isolated PC. In the present case, the nodule in the anterior segment of the left upper lobe was highly suspected to be lung cancer on radiology, and the nodule in the posterior basal segment of the left lower lobe was suspected to be pulmonary metastasis. Therefore, initially, the possibility of cryptococcus was not considered in advance, and thus, no non-invasive tests, such as cryptococcal antigen testing, were performed before percutaneous lung biopsy. PC symptoms are nonspecific, presenting with cough, sputum, fever, dyspnea, pleuritic chest pain, hemoptysis and malaise (3,29), which are indistinguishable from other causes of pneumonia (30). However, a subset of patients are asymptomatic and the condition is usually detected incidentally during chest radiological examination (23,31). The patient of the present study had no clinical symptoms, even with lung cancer of the upper lobe of the left lung. Different immune statuses may affect the CT imaging features of patients with PC (32). Based on previous literature and clinical experience, pulmonary nodules/masses, either solitary or multiple, were the most common CT findings in PC, which usually occurs in the peripheral lung, adjacent to or involving the pleura (29,32,33). As reported in previous studies, when PC consists of solitary or multiple nodules, these nodules may be confused with lung cancer on chest CT and it is often difficult to distinguish PC from lung carcinoma (5,16). Igai et al (34) tried to distinguish PC from lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET); however, their results showed that FDG-PET has difficulty distinguishing PC from malignancies. In the patient of the present study, the confirmed posterior basal pleural nodule of the left lower lobe was consistent with this CT feature and the final diagnosis was cryptococcal infection. In the present case, multiple nodules were found in the left lung and based on chest CT, it was highly suspected that the nodules in the anterior segment of the left upper lobe were peripheral lung cancer, while the other subpleural nodules in the posterior basal segment of the left lower lobe were intrapulmonary metastases, which were later confirmed by biopsy and surgery as adenocarcinoma and PC infection, respectively. These imaging features of the present case were consistent with those reported in the literature above. Huang et al (12) suggested that cryptococcosis lesions coexisted with lung cancer and resembled primary or metastatic tumors. Harada et al (16) indicated that, since most patients were in an immunocompetent state, the coexistence of cryptococcosis and carcinoma was coincidental. However, Robinson et al (9) thought that lung malignancy may have resulted in a degree of immune suppression, predisposing the patient to infection with cryptococcus. This issue is currently controversial and further studies are needed to clarify the possible relationship between lung cancer and cryptococcal infection. It may be speculated that there is another possibility that pulmonary cryptococcal infection can lead to the occurrence of lung cancer. Similarly, The coexistence of pulmonary tuberculosis and lung cancer is not an uncommon clinical observation (35), it has been proposed that chronic inflammation in the lungs due to tuberculosis may cause clastogenic activity in the DNA of bronchial epithelium. Another possibility is lateral gene transfer; since Mycobacterium tuberculosis is an intracellular organism, bacterial DNA may integrate into bronchial epithelial cells to induce neoplastic transformation (36). In addition, for cases co-existing in the same nodule or mass, latent cryptococcus infection may have a long-term chronic inflammatory stimulation, and there is vast preclinical and clinical evidence suggesting that strong and chronic inflammatory responses promote cancer development and progression through different mechanisms (37,38). The option that PC may cause lung cancer has not been reported, but it is worthy of further research. Histopathology is still the most important diagnostic method for PC and it is often necessary to combine special staining to obtain a definitive diagnosis. It has been reported that the detection rates of C. neoformans by PAS, GMS, MC and Alcian blue staining were 100, 100, 87 and 67%, respectively (39).

A comprehensive search of the PubMed, Google Scholar and Web of Science databases was conducted and only 17 cases of PC coexisting with pulmonary carcinoma have been reported in the English language worldwide, which were from Japan, China, South Korea and Australia (9,1117). The clinical characteristics of PC coexisting with pulmonary carcinoma in the previous literature are summarized in Table I. The patient of the present case study was asymptomatic; among the 17 patients reported in the literature, 6 were asymptomatic. Furthermore, 12 patients were immunocompetent and 5 patients had immunosuppressive and underlying diseases, including diabetes mellitus, a history of gastric cancer and thyroid adenoma resection, systemic lupus erythematosus, chronic viral hepatitis B and a history of hormone use. Compared with previous reports, the unique feature of the present case was the relatively small size of the lung cancer and PC nodule, which were 2.4×2.0 and 1.3×0.9 cm, respectively. The patient of the present study had no underlying diseases and was immunocompetent. Of the 17 patients reported in the literature, 7 were diagnosed with coexisting cryptococcosis and carcinoma within the same lobe; however, in the present case, the carcinoma nodule and cryptococcal nodule were not in the same lobe. As reported in the literature, the histological types of cancer in most cases were adenocarcinoma (13 cases), 2 cases were squamous cell carcinoma and 2 cases were alveolar cell carcinoma. The histological type of cancer in the case of the present study was adenocarcinoma. In terms of treatment, almost the same treatment method was adopted in the present case and the previous literature, namely surgical excision plus antifungal therapy. According to previous results, most of the patients had a good prognosis and the patient of the present case study was followed for 5 years with no recurrence of either disease.

Table I.

Features of previously reported cases of PC coinciding with lung cancer.

Table I.

Features of previously reported cases of PC coinciding with lung cancer.

Case no./age, years/sexAuthor, yearCountrySymptomsImmuno-suppressive underlying diseaseChest CT of lung cancer/PCHistologic subtypes of cancerLung cancer TNM stagingTherapyFollow-up time after dischargePrognosis(Refs.)
1/73/MAhn, 2005SouthMild dyspneaDiabetesAnterior segment ofModeratelypT1aN0M0Surgical10 monthsNo(11)
Koreaon exertionmellitus andthe right upper lobedifferentiated(Stage IA)excision + recurrence
and coughhypertension squamous cell AFT
carcinoma
2/74/MRobinson,AustraliaRight-sidedNoneLeft lower lobeModeratelypT2N1SurgicalNANA(9)
1999 pleuritic chest opacitydifferentiated(Stage IIB)excision +
pain and mild adenocarcinoma AFT
dyspnea
3/73/FKawasaki,JapanAsymptomaticNoneGGO, the leftAdenocarcinomapT1N0M0Surgical3 yearsNo(13)
2004 anterior superior (Stage IA)excision + recurrence
subsegment/two AFT
nodules, the left
anterior basal
segment
4/52/FLi, 2018ChinaCoughHistory ofSolitary nodule,AdenocarcinomapT1bN2M0Surgical3 yearsNo(14)
thyroidthe right posterior (Stage IIIA)excision + recurrence
adenoma segment/multiple ANCT +
resectionnodules, the right AFT
lateral basal
segment
5/72/MYao, 2020ChinaDry coughNoneIrregular mass, leftModerately-NASurgical5 yearsCancer(15)
hilum of the lung/poorly excision + recurrence
multiple nodules,differentiated AFT
dorsal segment ofsquamous cell
the right lower lobecarcinoma
6/64/FHuang.,ChinaCough andDiabetesSolitary nodule,Invasive ADCpT1aN0M0Surgical4 yearsNo(12)
2019 sputummellitusL-S3/solitary (Stage IA)excision + recurrence
production nodule, L-S7,8 AFT
7/55/MHuang,ChinaAsymptomaticNoneSNGGO, R-S6/Invasive ADCpT2aN0M0Surgical7 yearsNo(12)
2019 solitary nodule, (Stage IB)excision + recurrence
R-S3 AFT
8/69/FHuang.,ChinaAsymptomaticNoneSolitary nodule,Non-mucinousTisSurgical4 yearsNo(12)
2019 R-S2/multipleAIS excision + recurrence
nodules, R-S2a AFT
9/57/FHuang.,ChinaCough andGastricSolitary nodule,Invasive ADCpT1aN0M0Surgical4 yearsNo(12)
2019 sputumcancer afterL-S1/solitary (Stage IA)excision + recurrence
productionoperationnodule, R-S1a AFT
10/43/FHuang.,ChinaCough, chestNoneSolitary nodule,InvasivepT2aN0M0Surgical6 yearsCancer(12)
2019 distress and R-S3/solitarymucinous(Stage IB)excision + recurrence
chest pain nodule, R-S1aADC AFT +
ANCT
11/38/FHuang.,ChinaCough andNoneSolitary nodule,InvasivepT1bN2M0Surgical8 yearsCancer(12)
2019 phlegm with R-S2/solitarymucinous(Stage IIIA)excision + recurrence
blood nodule, R-S6ADC AFT +
ANCT
12/52/FHuang.,ChinaChest pain,NoneSNGGO, R-S2/Invasive ADCpT1aN0M0Surgical4 yearsNo(12)
2019 cough and multiple nodules, (Stage IA)excision + recurrence
sputum R-S6 AFT
production
13/67/FHuang.,ChinaFever? CoughNoneAir-spaceInvasivecT4N0MibAFT+10 monthsDeceased(12)
2019 and sputum consolidation,mucinous ADC(Stage IV)ANCT
production R-LL/air-space
consolidation, R-LL
14/69/MZheng,ChinaCoughNoneMultiple nodules,AdenocarcinomaNASurgical2 yearsNo(17)
2020 and chest the left upper lobe/ excision + recurrence
discomfort multiple nodules, AFT
the right lower lobe
15/54/MZheng,ChinaAsymptomaticNoneGGO, the posteriorAlveolar cellNASurgical2 yearsNo(17)
2020 segment of the rightcarcinoma excision + recurrence
upper lobe apex/ AFT
multiple nodules,
the left upper lobe
16/46/FZheng,ChinaAsymptomaticSystemic lupusMultiple nodules,Alveolar cellNASurgical2 yearsNo(17)
2020 erythematosus,the dorsal segmentcarcinoma excision + recurrence
chronic viralof the lower lobe AFT
hepatitis B andof the right lung/
use of methyl-solitary nodule, the
prednisoloneouter basal segment
sodiumof the lower lobe of
succinateright lung
17/71/MHarada,JapanAsymptomaticNoneSolitary thin-walledWell-T1N0M0NA1 yearNo(16)
2006 cavitary nodule, thedifferentiated(Stage IA) recurrence
apical segment ofpapillary
the right lungadenocarcinoma

a Coexisting cryptoccosis and carcinoma within the same lobe. ADC, adenocarcinoma; AFT, antifungal therapy; AIS, adenocarcinoma in situ; ANCT, antineoplastic chemotherapy; cTNM staging, clinical TNM staging; F, female; LL, lower lobe; M, male; NA, information not available; PC, pulmonary cryptococcosis; pTNM staging, pathological TNM staging; R, right; S, segment; SNGGO; solitary nodular ground-glass opacity.

The present case study reminds us of the possibility of dualism in the diagnosis of multiple pulmonary nodules based on CT examination, such as the coexistence of lung carcinoma and PC. If medical conditions permit, lesion resection should be performed to treat suspected malignant lung nodules, including cryptococcal nodules that do not respond to antifungal therapy.

Acknowledgements

Not applicable.

Funding

Funding: No funding was received.

Availability of data and materials

The datasets generated in the present study are not publicly available to protect the patient's privacy but are available from the corresponding author on reasonable request.

Authors' contributions

HW and MW were involved in the conception and design of the study. HW and XC drafted the manuscript and performed the acquisition, analysis and interpretation of data for the study. YT and YW made contributions to the interpretation of the data for the study and revised the manuscript critically for important intellectual content. DY and YW acquired pathological and surgical data of the patient/performed measurements. YZ and YL researched the clinical case, participated in the treatment of the patient and revised the manuscript. MW, HW and YT confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

This study was approved by the ethics committee of Taihe Hospital (Shiyan, China), and was performed in accordance with the principles of Good Clinical Practice following the Tri-Council guidelines.

Patient consent for publication

Written informed consent for anonymized information and images to be published in this article was obtained from the patient.

Competing interests

The authors declared that they have no competing interests.

References

1 

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, et al: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 50:291–322. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Yang R, Yan Y, Wang Y, Liu X and Su X: Plain and contrast-enhanced chest computed tomography scan findings of pulmonary cryptococcosis in immunocompetent patients. Exp Ther Med. 14:4417–4424. 2017.PubMed/NCBI

3 

Chang WC, Tzao C, Hsu HH, Lee SC, Huang KL, Tung HJ and Chen CY: Pulmonary cryptococcosis: Comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest. 129:333–340. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Wang RY, Chen YQ, Wu JQ, Wang X, Cao YH, Zhao HZ and Zhu LP: Cryptococcosis in patients with hematological diseases: A 14-year retrospective clinical analysis in a Chinese tertiary hospital. BMC Infect Dis. 17:4632017. View Article : Google Scholar : PubMed/NCBI

5 

Setianingrum F, Rautemaa-Richardson R and Denning DW: Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. Med Mycol. 57:133–150. 2019. View Article : Google Scholar : PubMed/NCBI

6 

Smith JA and Kauffman CA: Pulmonary fungal infections. Respirology. 17:913–926. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Qu J, Zhang X, Lu Y, Liu X and Lv X: Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China. Sci Rep. 10:93872020. View Article : Google Scholar : PubMed/NCBI

8 

Cheng KB, Wu ZH, Liang S, Li HP and Xu JF: Associations of serum cryptococcal antigen with different of clinical characteristics: A comprehensive analysis of 378 pulmonary cryptococcosis patients. Ann Palliat Med. 10:681–693. 2021. View Article : Google Scholar : PubMed/NCBI

9 

Robinson TD, Barnes DJ and Watson GF: Coexistent cryptococcosis and carcinoma within a solitary pulmonary nodule. Aust N Z J Med. 29:561–562. 1999. View Article : Google Scholar : PubMed/NCBI

10 

Howard J, Thompson TZ, MacArthur RD, Rojiani AM and White J: Widely disseminated cryptococcosis manifesting in a previously undiagnosed human immunodeficiency virus (HIV)-positive 18-year-old. Am J Case Rep. 21:e9244102020. View Article : Google Scholar : PubMed/NCBI

11 

Ahn IS, Kim HG, Ryu JS, Kim L, Kwak SM, Lee HL, Yoon YH and Cho JH: A case of pulmonary cryptococcosis with non-small cell lung cancer in idiopathic CD4+ T-lymphocytopenia. Yonsei Med J. 46:173–176. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Huang J, Lan C, Li H, Chen S, Lin Q and Weng H: Concomitant lung adenocarcinoma and pulmonary cryptococcosis confirmed by pathologic examinations. Medicine (Baltimore). 98:e183162019. View Article : Google Scholar : PubMed/NCBI

13 

Kawasaki H, Ishikawa K, Kuniyoshi M, Ohta M, Kawabata T and Hirayasu T: Lung adenocarcinoma with coexisting pulmonary cryptococcoma. Jpn J Thorac Cardiovasc Surg. 52:21–25. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Li L, Zhuang L, Zhou J and Shao C: Pulmonary cryptococcosis coexisting with adenocarcinoma: A case report and review of the literature. J Med Case Rep. 12:3272018. View Article : Google Scholar : PubMed/NCBI

15 

Yao K, Qiu X, Hu H, Han Y, Zhang W, Xia R, Wang L and Fang J: Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: A case report and literature review. BMC Pulm Med. 20:1612020. View Article : Google Scholar : PubMed/NCBI

16 

Harada T, Hakuma N, Kamimura A, Ito K and Okamoto K: Pulmonary cryptococcosis within a pulmonary carcinoma-review of reported cases. Intern Med. 45:369–372. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Zheng GX, Tang HJ, Huang ZP, Pan HL, Wei HY and Bai J: Clinical characteristics of pulmonary cryptococcosis coexisting with lung adenocarcinoma: Three case reports. World J Clin Cases. 8:6444–6449. 2020. View Article : Google Scholar : PubMed/NCBI

18 

Yuri T, Kimura A, Yoshizawa K, Emoto Y, Kinoshita Y and Tsubura A: Pulmonary and meningeal cryptococcosis after corticosteroid therapy for autoimmune hepatitis: Coexistence of cryptococci within pulmonary cancer nodule. Case Rep Pathol. 2013:8071972013.PubMed/NCBI

19 

Teixeira LM, Siqueira G, Shewmaker PL and Facklam RR: Manual of Clinical Microbiology. (10th edition). 2011.

20 

Diekema DJ, Pfaller MA and Murray PR: Infection control epidemiology and clinical microbiology. 2006.

21 

Murray GI: Laser Microdissection. Molecular Biomethods Handbook; 2008, View Article : Google Scholar

22 

Fang W, Fa Z and Liao W: Epidemiology of cryptococcus and cryptococcosis in China. Fungal Genet Biol. 78:7–15. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ and Weng XH: Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007. Med Mycol. 48:570–579. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Wang H, Wang L, Luo Z, Li D, Luo G, Ren T, You H, Liu Y, Tang Y and Wang M: Performance of rapid on-site evaluation of touch imprints of lung tissue biopsies for the diagnosis of pulmonary cryptococcosis in patients without HIV infection. Mycoses. 65:635–642. 2022. View Article : Google Scholar : PubMed/NCBI

25 

McFadden DC, Zaragoza O and Casadevall A: Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J Clin Microbiol. 42:2786–2788. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Fisher JF, Valencia-Rey PA and Davis WB: Pulmonary cryptococcosis in the immunocompetent patient-many questions, some answers. Open Forum Infect Dis. 3:ofw1672016. View Article : Google Scholar : PubMed/NCBI

27 

Mukhopadhyay S, Farver CF, Vaszar LT, Dempsey OJ, Popper HH, Mani H, Capelozzi VL, Fukuoka J, Kerr KM, Zeren EH, et al: Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries. J Clin Pathol. 65:51–57. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Tang MW, Clemons KV, Katzenstein DA and Stevens DA: The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time. Crit Rev Microbiol. 42:634–642. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Ye F, Xie JX, Zeng QS, Chen GQ, Zhong SQ and Zhong NS: Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Lung. 190:339–346. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Chang CC, Sorrell TC and Chen SC: Pulmonary cryptococcosis. Semin Respir Crit Care Med. 36:681–691. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Kohno S, Kakeya H, Izumikawa K, Miyazaki T, Yamamoto Y, Yanagihara K, Mitsutake K, Miyazaki Y, Maesaki S, Yasuoka A, et al: Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. J Infect Chemother. 21:23–30. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Xie LX, Chen YS, Liu SY and Shi YX: Pulmonary cryptococcosis: Comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol. 56:447–453. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Lacomis JM, Costello P, Vilchez R and Kusne S: The radiology of pulmonary cryptococcosis in a tertiary medical center. J Thorac Imaging. 16:139–148. 2001. View Article : Google Scholar : PubMed/NCBI

34 

Igai H, Gotoh M and Yokomise H: Computed tomography (CT) and positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg. 30:837–839. 2006. View Article : Google Scholar : PubMed/NCBI

35 

Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QS and Zhou BS: Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: A systematic review. Int J Cancer. 125:2936–2944. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Molina-Romero C, Arrieta O and Hernández-Pando R: Tuberculosis and lung cancer. Salud Publica Mex. 61:286–291. 2019. View Article : Google Scholar : PubMed/NCBI

37 

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

38 

Engels EA: Inflammation in the development of lung cancer: Epidemiological evidence. Expert Rev Anticancer Ther. 8:605–615. 2008. View Article : Google Scholar : PubMed/NCBI

39 

Yi XH, Kong J, Zhu MF, Zhang Y, Chen XF and Zhong CS: Pathological diagnosis and ultrastructure features of primary pulmonary cryptococcosis: A study of 27 cases. Zhonghua Bing Li Xue Za Zhi. 33:424–428. 2004.(In Chinese). PubMed/NCBI

Related Articles

Journal Cover

February-2024
Volume 27 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang H, Chen X, Wang Y, Yu D, Zhou Y, Liu Y, Tang Y and Wang M: Pulmonary cryptococcosis coexisting with lung adenocarcinoma: A case report and review of the literature. Oncol Lett 27: 47, 2024.
APA
Wang, H., Chen, X., Wang, Y., Yu, D., Zhou, Y., Liu, Y. ... Wang, M. (2024). Pulmonary cryptococcosis coexisting with lung adenocarcinoma: A case report and review of the literature. Oncology Letters, 27, 47. https://doi.org/10.3892/ol.2023.14179
MLA
Wang, H., Chen, X., Wang, Y., Yu, D., Zhou, Y., Liu, Y., Tang, Y., Wang, M."Pulmonary cryptococcosis coexisting with lung adenocarcinoma: A case report and review of the literature". Oncology Letters 27.2 (2024): 47.
Chicago
Wang, H., Chen, X., Wang, Y., Yu, D., Zhou, Y., Liu, Y., Tang, Y., Wang, M."Pulmonary cryptococcosis coexisting with lung adenocarcinoma: A case report and review of the literature". Oncology Letters 27, no. 2 (2024): 47. https://doi.org/10.3892/ol.2023.14179